The federal government’s long-awaited shift on cannabis policy is officially underway, and for medical marijuana operators, the implications are immediate with cannabis rescheduling Schedule III.
Following a sweeping directive from the U.S. Department of Justice and the Drug Enforcement Administration, certain cannabis products have now been moved to Cannabis Rescheduling Schedule III under the Controlled Substances Act (CSA), marking a historic departure from decades of Schedule I classification. At the same time, regulators are fast-tracking a broader review that could permanently redefine marijuana’s status under federal law.
What Changed – and What Happens Next – Cannabis Rescheduling
Under an order issued by Acting Attorney General Todd Blanche, FDA-approved cannabis products and state-licensed medical marijuana are now immediately recognized as Schedule III substances. This shift is designed to expand research opportunities, improve patient access, and align federal policy more closely with the realities of state-regulated medical programs.
However, this is only the beginning.
A formal administrative hearing set to begin June 29, 2026 will determine whether marijuana as a whole should be fully rescheduled from Schedule I to Schedule III. That process is expected to move more quickly than previous attempts, after regulators scrapped earlier proceedings in favor of a more streamlined approach.
DEA Registration Portal: What Businesses Need to Know
In tandem with the rescheduling announcement, the DEA has launched a Medical Marijuana Dispensary Registration Portal, opening the door for state-licensed operators to access federal protections tied to Schedule III status. The portal went live on April 29 at 12pm EST.
According to the DEA’s official application instructions, businesses seeking registration should be prepared for a rigorous review process. The application requires detailed disclosures across several operational areas, including:
- Storage and security protocols (vaults, safes, alarm systems, access controls)
- Inventory management and recordkeeping procedures
- Ordering, dispensing, and handling processes
- Employee access to controlled substances, including background information
- Supplier relationships and sourcing plans
- Any repackaging or relabeling activities
Applicants must also provide documentation of their state cannabis licenses and disclose any relevant criminal or disciplinary history tied to the business or its personnel.
The registration comes with an annual, non-refundable fee of $794, and currently only supports PayPal payments, though additional payment methods are expected in the near future.
New Federal Oversight Model
One of the more unusual components of the new framework is how cannabis production will be handled at the federal level.
To comply with international treaty obligations, the federal government will act as a technical “middleman” in cannabis transactions. Registered manufacturers will be required to:
- Store cannabis in DEA-accessible facilities
- Sell their crops to the federal government at a nominal price
- Repurchase the same products with an added administrative fee
While largely procedural, this structure introduces a new layer of federal oversight that operators will need to understand and navigate.
Tax and Compliance Implications
The move to Schedule III could significantly reshape the financial landscape for cannabis businesses.
Most notably, it may allow companies to bypass the limitations of IRS Code Section 280E, which has historically prevented cannabis operators from deducting standard business expenses. The Internal Revenue Service has already indicated that updated guidance is forthcoming.
However, these benefits are not automatic. Businesses must first complete the DEA registration process and demonstrate compliance with federal requirements, raising the bar for operational transparency and internal controls.
A Turning Point for the Industry
The Trump administration has framed the cannabis rescheduling effort as both a healthcare and public policy priority, citing growing public support and patient demand for medical cannabis access.
At the same time, federal officials have emphasized that enforcement against illicit markets and drug trafficking will remain a top priority, even as legal frameworks evolve.
For cannabis operators, the message is clear: opportunity is expanding – but so is scrutiny.
Key Takeaway for Operators
This isn’t just a policy shift… it’s a compliance inflection point.
Businesses that want to benefit from federal protections and tax relief must be ready to operate at a higher regulatory standard. That means tightening security protocols, formalizing procedures, and ensuring every aspect of the operation can withstand federal review.
Those who prepare early will be best positioned to capitalize on the advantages of Schedule III. Those who don’t may find themselves locked out of the system – or exposed to new risks.
Need Help Navigating DEA Registration and Federal Compliance?
This new framework introduces a level of federal oversight that most cannabis operators have never had to navigate before, and the margin for error is shrinking fast.
Canna Business Services helps cannabis businesses prepare for moments exactly like this.
From DEA registration readiness and SOP development to compliance audits and recordkeeping systems, our team works with operators to ensure they meet both state and emerging federal requirements with confidence.
Don’t wait until your application is rejected or your operations are flagged. Get ahead of the transition and position your business for success under Schedule III.
